Article Type
Case Report
Published
The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. This study aimed to assess the safety, immunogenicity, and pharmacokinetics of an extended seven-dose regimen of palivizumab in children at high risk for serious infection by the RSV.